> Detailanzeige

Mariottini, Alice; De Matteis, Eleonora; Cencioni, Maria Teresa; Muraro, Paolo A.

Haematopoietic Stem Cell Transplantation for the Treatment of Multiple Sclerosis: Recent Advances

Literatur-
verwaltung

Zur
Merkliste

Lösche von
Merkliste

Per Whatsapp teilen

Schließen

Merkliste



Sie können Bookmarks mittels Listen verwalten, loggen Sie sich dafür bitte in Ihr SLUB Benutzerkonto ein.
  • Medientyp: E-Artikel
  • Titel: Haematopoietic Stem Cell Transplantation for the Treatment of Multiple Sclerosis: Recent Advances
  • Beteiligte: Mariottini, Alice; De Matteis, Eleonora; Cencioni, Maria Teresa; Muraro, Paolo A.
  • Erschienen: Springer Science and Business Media LLC, 2023
  • Erschienen in: Current Neurology and Neuroscience Reports, 23 (2023) 9, Seite 507-520
  • Sprache: Englisch
  • DOI: 10.1007/s11910-023-01290-2
  • ISSN: 1528-4042; 1534-6293
  • Entstehung:
  • Hochschulschrift:
  • Anmerkungen:
  • Beschreibung: <jats:title>Abstract</jats:title><jats:sec> <jats:title>Purpose of Review</jats:title> <jats:p>Autologous haematopoietic stem cell transplantation (AHSCT) is increasingly considered a treatment option for patients with multiple sclerosis (MS), an autoimmune demyelinating and degenerative disease of the central nervous system (CNS). AHSCT persistently suppresses inflammation and improves the disease course in large proportions of patients with relapsing–remitting (RR) MS. Aim of this article is to review the relevant new knowledge published during the last 3 years.</jats:p> </jats:sec><jats:sec> <jats:title>Recent Findings</jats:title> <jats:p>Laboratory studies reported confirmatory and new insights into the immunological and biomarker effects of AHSCT. Retrospective clinical studies confirmed excellent outcomes in RRMS, showing possible superior effectiveness over standard therapies and suggesting a possible benefit in early secondary progressive (SP) MS with inflammatory features. New data on risks of infertility and secondary autoimmunity were also reported.</jats:p> </jats:sec><jats:sec> <jats:title>Summary</jats:title> <jats:p>Further evidence on the high effectiveness and acceptable safety of AHSCT strengthens its position as a clinical option for aggressive RRMS. Further research is needed to better define its role in treatment-naïve and progressive forms of MS, ideally within randomised clinical trials (RCTs).</jats:p> </jats:sec>